Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
-
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
-
Hydron Energy Demonstrates Low-Cost Production of Xenon with Negative Carbon Footprint for Satellite Propulsion
-
Greenberg Traurig Continues Asia Expansion with Addition of Alfred Ng in Singapore
-
Using Balance Transfer Credit Cards to Pay Off Debt Faster
-
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others
-
FPT Strengthens South Korea Footprint with Strategic Partnership and Investment in Blueward
-
Hotel Okura to Open The Okura Resort Hakone Gora in 2029
-
Skyline Digital Marketing Introduces Proprietary Skyline Methodology to Strengthen Data-Driven Business Growth
-
Global Times: Mogao Caves' mural paintings meet modern technology
-
GoTyme Bank Launches Crypto Trading in the Philippines in Partnership with Alpaca
-
TOYOTA GAZOO Racing and Lexus Hold World Premiere of GR GT, GR GT3, and Lexus LFA Concept
-
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
-
Fujitsu and Scaleway partner to accelerate European sustainable transformation and data sovereignty with FUJITSU-MONAKA CPU-based AI inference
-
TOYOTA GAZOO Racing World Premieres GR GT & GR GT3
-
Lexus World Premieres Lexus LFA Concept BEV Sports Car
-
NEC Orchestrating Future Fund Invests in PopID, Inc. to Accelerate Global Expansion of Biometric Payment Solutions and Launch a Strategic Collaboration
-
World's First General Design Approval (GDA) for Developed Steel and Post-Weld Heat Treatment (PWHT) Exemption based on ECA for Low-pressure Liquefied CO2 Tank made of KF460 steel
-
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
-
Hitachi at CES 2026: Building a Harmonized Society Through Technology
-
Mitsubishi Motors Launches the All-New Destinator in Vietnam
-
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
-
Global Times: Xi Jinping Thought on Economy guides long-term steady economic growth for China: Jin Sheping
-
Linux Foundation Research Releases New Report: "The State of Open Source Japan 2025: Accelerating Business Value through Strategic Open Source Engagement"
-
Linux Foundation Welcomes Mitsubishi Electric as Gold Member During Open Source Summit Japan
-
AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore
-
RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION
-
Edgewater Wireless Announces Completion of Eleventh and Twelfth Payments of Debenture Interest
-
ALLUONE Launches IoT-Based Home Smart Garden 'Watering Garden'
-
Turnbull & Asser Appoints Roberto Menichetti as Creative Director
-
Gigaphoton Excimer Laser for Advanced Packaging Installed at Japanese Company
-
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
-
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
-
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Am
-
Sustainability Focus Session 2025
-
Matthews International Provides Update on Actions to Create Shareholder Value and Addresses Director Nominations
-
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
-
Anchorage Digital Integrates Middleware Provider BridgePort to Enhance Institutional Settlement Infrastructure
-
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
-
Panah Master Fund Counters M&A Capital Partners’ Rebuttal to its Previously Submitted Shareholder Proposals
-
Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For
-
Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For
-
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
-
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
-
Drilling hits wide zone of mineralisation in new area well outside resource
-
Gartner Announces Gartner Finance Symposium/Xpo 2026 in Sydney
-
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
-
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
-
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and
